Análisis Argos
ICUI
ICUICara
ICU Medical, Inc. · Healthcare
US$ 165.78
precio al 2026-07-28
Valor justo Argos*
Sin estimar
vs. su valor justo
Sin estimar
Score Argos
37/100
LA RESPUESTA
El mercado le pide crezca 53.8% al año — más de lo que ha demostrado (3.1%). Estás pagando un futuro que todavía no probó: el margen de error es mínimo.
Recompensas
Sin recompensas destacadas.
Riesgos
!El precio pide más crecimiento del que la empresa ha demostrado.
!Balance frágil: la deuda pesa sobre el negocio.
VALOR1/6FUTURO4/6PASADO1/6SALUD2/6DIVIDENDO1/6
El Iris de calidad
VALOR1/6FUTURO4/6PASADO1/6SALUD2/6DIVIDENDO1/6
ValorCotiza por encima de su valor justo
FuturoIngresos creciendo con fuerza
PasadoHistorial débil
SaludBalance razonable
DividendoEl dividendo aún duerme
Score Argos37de 100Cara
Ingresos6%
US$ 2.2 B
Margen operativo167%
4.8%
Flujo de caja libre25%
US$ 0.1 B
Deuda neta
US$ 1.1 B
Lo esencial, sin ruido
Cap. de mercadoUS$ 4.1B
P/E5660.3x
EV/EBITDA16.1x
FCF yield2.2%
ROIC1.7%
Margen operativo4.8%
Crecim. ingresos-6.4%/año
Piotroski F6/9
Competidores

Los rivales, con el mismo ojo

El Iris de calidad de cada competidor, lado a lado. Tocá uno para ver su análisis.

Novedades

Noticias recientes

prnewswire.com · 9 jul
Otsuka ICU Medical LLC Announces Over $500M Expansion of IV Solutions Manufacturing in North America
This expansion of IV solutions manufacturing will help enhance supply-chain resiliency, support portfolio development and advance non-DEHP innovation for the North American IV solutions market. Joint venture announces over $500M IV solutions manufacturing expansion in Austin, TX Expansion aimed at improving IV solutions supply resiliency and quality, and accelerating non-DEHP new product development in North America via fully automated technology First major milestone toward fulfilling the commitments of the joint venture finalized in May 2025 between ICU Medical, Inc. and Otsuka Pharmaceutical Factory America, Inc. AUSTIN, Texas, July 9, 2026 /PRNewswire/ -- Otsuka ICU Medical LLC today announced plans for an over $500 million expansion to its US IV solutions manufacturing through a new facility and significant upgrades to its existing operations in Austin, Texas.
zacks.com · 8 jul
ICUI vs. SYK: Which Stock Should Value Investors Buy Now?
Investors looking for stocks in the Medical - Products sector might want to consider either ICU Medical (ICUI) or Stryker (SYK). But which of these two stocks offers value investors a better bang for their buck right now?
zacks.com · 18 jun
ICUI or MDLN: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Products sector might want to consider either ICU Medical (ICUI) or Medline (MDLN). But which of these two companies is the best option for those looking for undervalued stocks?
benzinga.com · 15 jun
This ICU Medical Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
fool.com · 10 jun
ICU Medical's General Counsel Sells — The Smiths Integration Is Almost Done, the Proof Isn'tICU Medical's General Counsel Sells — The Smiths Integration Is still playing out.
2,447 shares sold for a transaction value of ~$304,000. This sale represented 11.17% of Sanzone's direct holdings.
zacks.com · 8 may
Implied Volatility Surging for ICU Medical Stock Options
Investors need to pay close attention to ICUI stock based on the movements in the options market lately.
seekingalpha.com · 8 may
ICU Medical, Inc. (ICUI) Q1 2026 Earnings Call Transcript
ICU Medical, Inc. (ICUI) Q1 2026 Earnings Call Transcript
zacks.com · 7 may
ICU Medical (ICUI) Tops Q1 Earnings and Revenue Estimates
ICU Medical (ICUI) came out with quarterly earnings of $1.97 per share, beating the Zacks Consensus Estimate of $1.78 per share. This compares to earnings of $1.72 per share a year ago.

* Valor justo Argos: estimación educativa del valor intrínseco según el propio flujo de caja de la empresa y su capacidad de crecimiento — no un precio objetivo ni una recomendación. Esto es información y educación, no asesoría de inversión. Rendimiento pasado no garantiza resultados futuros.